Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea.


Journal

Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132

Informations de publication

Date de publication:
Historique:
pubmed: 19 11 2019
medline: 4 8 2021
entrez: 19 11 2019
Statut: ppublish

Résumé

This study aimed to explore whether and how anti-lysyl oxidase (anti-LOX) combined with a vacuum device (VD) could promote penile lengthening and to evaluate the effect on erectile function. This study was performed on four groups of adult rats: control, anti-LOX, VD (negative pressure value of -300 mmHg), and anti-LOX + VD. Penile length was measured by a modified VD method and verified on exposed length data. Intracavernous pressure (ICP) and maximum ICP/mean arterial pressure (MAP) ratio were recorded to assess erectile function. For corpus cavernosum, LOX activity and concentrations of pyridinoline, desmosine, hydroxyproline, and elastin were analyzed; transmission electron microscope and Hart's elastin staining were performed to monitor microstructural changes. Anti-LOX and VD significantly lengthened the penis by 10.8% (3.75 mm) and 8.2% (2.48 mm) compared with the control group, respectively, while anti-LOX + VD achieved the longest penile size (40.58 ± 0.40 mm) which was 17.4% longer than the control group (34.58 ± 0.54 mm). After 1-week washout, no penile retraction was observed. Meanwhile, exposed penile length data confirmed that the penis in the anti-LOX + VD group was also significantly longer. Anti-LOX inhibited LOX activity to reduce pyridinoline level, which led the penile tunica albuginea remodeling. However, it had no effect on hydroxyproline, desmosine, and elastin levels. Moreover, anti-LOX had no impact on erectile function, which was determined by ICP and ICP/MAP ratio. These results suggest that anti-LOX elongates the penis by reducing pyridinoline, which induces tunica albuginea remodeling. This lengthening effect was more obvious when combined with a VD. All procedures had no impact on erectile function.

Identifiants

pubmed: 31736474
pii: 271074
doi: 10.4103/aja.aja_120_19
pmc: PMC7523611
doi:

Substances chimiques

Amino Acids 0
Enzyme Inhibitors 0
Desmosine 11003-57-9
beta-aminopropionitrile fumarate 1119-28-4
Aminopropionitrile 151-18-8
pyridinoline 63800-01-1
Collagen 9007-34-5
Elastin 9007-58-3
Protein-Lysine 6-Oxidase EC 1.4.3.13
Hydroxyproline RMB44WO89X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

485-492

Déclaration de conflit d'intérêts

None

Références

J Cell Mol Med. 2018 Mar;22(3):2018-2022
pubmed: 29278308
J Sex Med. 2009 Dec;6(12):3247-53
pubmed: 19758281
J Sex Med. 2011 Jul;8(7):2112-7
pubmed: 21492409
Circulation. 2002 Nov 5;106(19):2503-9
pubmed: 12417550
J Sex Med. 2013 Jan;10(1):294-303
pubmed: 22512935
FASEB J. 2014 Jun;28(6):2725-35
pubmed: 24614760
BJU Int. 2009 Mar;103(6):793-7
pubmed: 18990153
BJU Int. 1999 Dec;84(9):1093-4
pubmed: 10571642
J Mol Histol. 2004 Nov;35(8-9):845-55
pubmed: 15609098
J Pediatr Endocrinol Metab. 2016 Feb;29(2):173-7
pubmed: 26352087
Cardiovasc Res. 1981 Jul;15(7):373-81
pubmed: 7307020
Eur Urol. 2006 Apr;49(4):609-11
pubmed: 16439051
J Sex Med. 2008 Jun;5(6):1468-73
pubmed: 18373527
J Pathol. 2015 Jul;236(3):373-83
pubmed: 25788370
Br J Urol. 1997 Jan;79(1):47-53
pubmed: 9043496
Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2228-33
pubmed: 15951346
J Urol. 1999 Apr;161(4):1141-4
pubmed: 10081856
J Sex Med. 2011 Nov;8(11):3188-92
pubmed: 20102448
Toxicol Appl Pharmacol. 2010 Apr 15;244(2):156-61
pubmed: 20045017
J Sex Marital Ther. 2010;36(2):118-23
pubmed: 20169492
Nat Rev Urol. 2012 Sep;9(9):499-507
pubmed: 22890302
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H1067-75
pubmed: 22904155
Atherosclerosis. 1998 Sep;140(1):135-45
pubmed: 9733224
J Urol. 1995 Aug;154(2 Pt 2):825-9
pubmed: 7609189
Circulation. 2012 Dec 18;126(25):3070-80
pubmed: 23136157
J Hand Surg Br. 1998 Jun;23(3):297-302
pubmed: 9665512
J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):301-13
pubmed: 8639466
J Biol Chem. 2015 Jun 26;290(26):16440-50
pubmed: 25979340
J Androl. 2012 Jul-Aug;33(4):651-9
pubmed: 22016353
Arch Pediatr Adolesc Med. 2010 Dec;164(12):1152-7
pubmed: 21135345
Int J Androl. 2010 Feb;33(1):e144-52
pubmed: 19656234
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H1-9
pubmed: 20472764
J Biomech. 2006;39(16):2983-90
pubmed: 16386746
Br J Urol. 1994 May;73(5):566-71
pubmed: 8012781
Curr Opin Urol. 2008 Nov;18(6):583-8
pubmed: 18832943
Asian J Androl. 2014 Nov-Dec;16(6):817-23
pubmed: 24994782
J Pediatr. 1999 May;134(5):579-83
pubmed: 10228293
BJU Int. 2011 Apr;107(8):1278-82
pubmed: 20868389
J Urol. 1994 Aug;152(2 Pt 2):734-9
pubmed: 8022007
Andrologia. 2018 Sep;50(7):e13051
pubmed: 29806152
Asian J Androl. 2004 Dec;6(4):365-8
pubmed: 15546031
Asian J Androl. 2019 Sep-Oct;21(5):516-521
pubmed: 30924453
J Hand Surg Br. 1994 Aug;19(4):522-7
pubmed: 7964107
Br J Urol. 1998 Nov;82(5):673-81
pubmed: 9839582
Sci Rep. 2017 Nov 2;7(1):14949
pubmed: 29097758
J Sex Med. 2017 Oct;14(10):1270-1276
pubmed: 28923308
Toxicol Appl Pharmacol. 2009 Sep 15;239(3):258-67
pubmed: 19524603
Eur Urol. 2010 Nov;58(5):773-80
pubmed: 20674151

Auteurs

Tao Li (T)

Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.

Fu-Dong Fu (FD)

Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.

Chang-Jing Wu (CJ)

Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.

Feng Qin (F)

Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.

Run Wang (R)

Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Jiu-Hong Yuan (JH)

Andrology Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH